Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple cone test predict fall risk in multiple sclerosis?

NCT ID NCT07786987

Diagnosis Sponsor: Hacettepe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study evaluates whether the Cone Evasion Walk Test—a walking task that involves stepping around cones—is a reliable and valid way to assess balance, obstacle avoidance, and fall risk in people with multiple sclerosis (MS). Researchers will measure how consistent the test results are across repeated sessions and compare them with established mobility and balance measures. The study includes 50 adults with MS who can walk independently, aiming to determine if this test is a useful clinical tool for this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cone Evasion Walk Test (a performance-based walking assessment)
What this could lead to
If reliable and valid, this test could become a standard tool to assess walking and fall risk in people with multiple sclerosis, helping guide rehabilitation.
What could go wrong
This is a small, early-stage study focused on measurement properties, not treatment outcomes. The test may not prove reliable or valid in this population, and results may not generalize beyond the study group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adults with a confirmed diagnosis of multiple sclerosis who meet the predefined eligibility criteria. Participants will be recruited from individuals with multiple sclerosis and will undergo the Cone Evasion Walk Test and standardized clinical assessments to investigate the reliability and validity of the test in this population.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Confirmed diagnosis of Multiple Sclerosis according to the 2017 revised McDonald criteria Age between 18 and 65 years Expanded Disability Status Scale (EDSS) score ≤6.0 Clinically stable, with no MS relapse within the previous 30 days Able to walk at least 10 meters independently, with or without a unilateral assistive device Able to understand and follow study instructions Willing and able to provide written informed consent Exclusion Criteria: MS relapse within the previous 30 days Cognitive impairment that prevents understanding of instructions or completion of the study assessments Co-existing orthopedic, cardiovascular, vestibular, or neurological conditions other than MS that significantly affect gait, balance, or safe performance of the CEW Severe uncorrected visual impairment that may interfere with obstacle detection Wheelchair-dependent mobility or requirement for bilateral walking aids Change in MS-related medication within the previous 30 days Participation in a structured exercise or rehabilitation program within the previous 4 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Function are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Function Multiple sclerosis Pain management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erciyes University Faculty of Medicine Hospitals

    Erciyes, Kayseri, 38039, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.